Phico Therapeutics phicotx.co.uk


Public lists: Pharma Startups (6570)

Phico Therapeutics is developing SASPject PT3.8, an antibacterial therapy for the systemic treatment of patients with serious Pseudomonas aeruginosa (P. aeruginosa) infections, which have a high mortality rate.

Phico Therapeutics is developing SASPject PT3.8, an antibacterial therapy for the systemic treatment of patients with serious Pseudomonas aeruginosa (P. aeruginosa) infections, which have a high mortality rate.

Company (Alive / Active)

Phone: +44(0)1954 741040

Fax:

Bertarelli, Building, Bourn Hall
High Street, Bourn
Cambridgeshire, CB23 2TN
England, United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Phico Therapeutics $1.9M Aug 1, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Phico Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Innovate UKGovernmentWiltshire, England, United KingdomGrant
Cambridge Capital GroupAngel Investor (Group)Cambridge, England, United KingdomOther Investors
Cambridge Research & InnovationCorporationOther Investors
Jordans GroupCorporationBristol, England, United KingdomOther Investors
ETCapitalVenture CapitalUnited StatesOther Investors
See all 9 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 15 competitors